Abstract: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.

Abstract: The present invention relates to at least one human EPO receptor agonist methods for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.

Abstract: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.

Abstract: IL-1 delta polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing IL-1 delta peptides are polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases (e.g. osteoporosis), cancer (e.g. lymphoproliferative disorders), atherosclerosis, and Alzheimer's disease, among others, and diagnostic assays for such conditions.